365 filings
8-K
REPL
Replimune Group Inc
4 Jan 23
Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer
9:15am
4
Esposito Pamela
13 Dec 22
Replimune / Pamela Esposito ownership change
8:01pm
8-K
REPL
Replimune Group Inc
12 Dec 22
Replimune Announces Proposed Public Offering
5:00pm
424B5
REPL
Replimune Group Inc
12 Dec 22
Prospectus supplement for primary offering
6:03am
424B5
REPL
Replimune Group Inc
7 Dec 22
Prospectus supplement for primary offering
4:58pm
8-K
REPL
Replimune Group Inc
7 Dec 22
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
7:15am
SC 13D/A
REPL
Replimune Group Inc
6 Dec 22
Replimune / Atlas Venture Fund X ownership change
5:00pm
4
REPL
Replimune Group Inc
5 Dec 22
Replimune / Konstantinos Xynos ownership change
8:01pm
3
Konstantinos Xynos
5 Dec 22
Replimune / Konstantinos Xynos ownership change
8:00pm
SC 13G/A
Redmile Group, LLC
18 Nov 22
Replimune / Redmile ownership change
5:17pm
10-Q
2023 Q2
REPL
Replimune Group Inc
3 Nov 22
Quarterly report
8:13am
8-K
REPL
Replimune Group Inc
3 Nov 22
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
8:11am
8-K
REPL
Replimune Group Inc
7 Oct 22
Entry into a Material Definitive Agreement
8:20am
SC 13D/A
REPL
Replimune Group Inc
14 Sep 22
Replimune / Atlas Venture Fund X ownership change
5:06pm
8-K
REPL
Replimune Group Inc
8 Sep 22
Submission of Matters to a Vote of Security Holders
4:10pm
10-Q
2023 Q1
REPL
Replimune Group Inc
4 Aug 22
Quarterly report
8:13am
8-K
REPL
Replimune Group Inc
4 Aug 22
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
8:10am
EFFECT
REPL
Replimune Group Inc
28 Jul 22
Notice of effectiveness
12:16am
DEFA14A
REPL
Replimune Group Inc
27 Jul 22
Additional proxy soliciting materials
8:29am
DEF 14A
REPL
Replimune Group Inc
27 Jul 22
Definitive proxy
8:27am